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Abstract The cryptophycins are newly discovered antimitotic 
agents isolated from the eyanobacterium Nostoc. Previous stud- 
ies using cultured cells demonstrated that microtubules are the 
target of these compounds. We have studied the interaction of 
cryptophycin 1 with tubulin and microtubules in vitro. Crypto- 
phycin 1 is an effective inhibitor of tubulin polymerization, causes 
tubulin to aggregate, and depolymerizes mierotubules to linear 
polymers omewhat similar to the spiral-like structures produced 
by the Vinca alkaloids. Cryptophyein I also inhibits vinblastine 
binding to tubulin but not colchicine binding. Thus, it appears that 
the cryptophycins may bind to the Vinca site in tubulio or to a 
site that overlaps with the Vinca site. 
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2. Materials and methods 
2.1. Materials 
Microtubule protein was isolated from bovine brain by two cycles of 
assembly and disassembly [7]. Tubulin was purified from microtubule 
protein by phosphocellulose chromatography [8]. [3H]VLB sulfate was 
purchased from Moravek Biochemicals. VLB was obtained from Sigma 
Chemical Co. Cryptophycin 1 was a gift from Merck, Sharp & Dohme 
Research Laboratories. 
2.2. Polymerization assays 
Two assays were used to measure the effectiveness of cryptophycin 
1. Tubulin at 1.5 mg/ml (15 ¢tM) was incubated at 37°C in PEM buffer 
containing 0.5 mM GTP, 8% DMSO and varying concentrations of
cryptophycin 1.The polymerization reaction was followed by measur- 
ing the increase in apparent absorbance at350 nm as a function of time 
or by sedimenting polymer after a 15 min incubation and measuring the 
concentration of unpolymerized protein in the supernatant. 
1. Introduction 
The cryptophycins are natural products isolated from cyano- 
bacteria nd have been found to be highly cytotoxic [1], having 
strong antifungal [2-5] and antitumor [6] activities. The struc- 
ture of cryptophycin 1, the major cryptophycin extracted from 
Nostoc sp. GSV224 [6] is shown in Fig. 1. This compound has 
antitumor activity against six tumors in vivo [6] and is much 
more effective against multidrug resistant strains of cell lines 
than vinblastine (VLB), colchicine, and paclitaxel [1]. 
Antimitotic drugs which act on tubulin and microtubules can 
be classified according to their site of interaction; the colchi- 
cine, Vinca alkaloid, or paclitaxel site. Drugs in the colchicine 
and Vinca classes inhibit tubulin polymerization and destabilize 
microtubules. Those in the paclitaxel class promote tubulin 
assembly and hyperstabilize microtubules. Cryptophycin 1 
causes the depletion of microtubules in A-10 vascular smooth 
muscle cells [1], suggesting that its target molecule is tubulin 
and that it binds to either the colchicine or Vinca sites, although 
data on its interaction with tubulin have not been published. 
This report describes the effect of cryptophycin 1 on tubulin 
assembly and microtubules in vitro and indicates that this new 
antimitotic agent may bind to the Vinca site on tubulin. 
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Abbreviations: PEM buffer, 0.1 M piperazinediethanesulfonate; 1 mM
ethyleneglycol bis(fl-aminoethyl ether)-N,N,N',N'-tetraacetic acid, 1 
mM MgSO4, pH 6.9; DMSO, dimethylsulfoxide; VLB, vinblastine. 
2.3. Vinblastine and colchicine binding 
Binding of [3H]VLB to tubulin was measured by column centrifuga- 
tion as described previously [9]. Solutions of 5 ¢tM tubulin and 5/zM 
[3H]VLB (3.5 x 104 DPM/nmol), with or without cryptophycin 1,were 
incubated in PEM buffer on ice for 15 min and 200 ¢tl were centrifuged 
through a 1 ml column of Sephadex G-25 prepared in PEM buffer. The 
eluate was analyzed for protein by the Bradford method [10] and for 
radioactivity by scintillation counting. 
Colchicine binding was measured using a fluorescence assay. Col- 
chicine itself has little fluorescence when irradiated with 350 nm radia- 
tion but upon binding to tubulin the antimitotic drug has strong fluores- 
cence, with an emission maximum at 432 nm [11]. Tubulin (3 pM) and 
colchicine (6/tM) were incubated for 1 h at 37°C in the absence and 
presence of 30 ¢tM cryptophycin 1.Podophyllotoxin, a drug known to 
bind to the colchicine site, was used as a positive control. Relative 
fluorescence was measured in a Perkin Elmer MPF-44B spec- 
trofluorometer at432 nm using 350 nm as the excitation wavelength. 
Measurements were done against a blank of tubulin alone. 
2.4. Electron microscopy 
Microtubule protein was polymerized tosteady state and 40/.tM VLB 
or 40 ,uM cryptophycin 1 was added. After varying time periods am- 
ples were removed and diluted 5-fold into 1% glutaraldehyde in PEM 
buffer. After several hours in glutaraldehyde samples were added to 
formvar- and carbon-coated grids, stained with a 2% uranyl acetate 
solution, and viewed in a JEOL JEM-1200 EXII electron microscope. 
3. Results and discussion 
3.1. Interaction of cryptophycin 1 with tubulin and microtubules 
Cryptophycin 1is an effective inhibitor of tubulin self-assem- 
bly (Fig. 2). At a tubulin concentration of 15 pM,  the concen- 
tration which caused 50% inhibition was 1 ¢tM. This IDso value 
is similar to that determined for VLB and colchicine (data not 
shown) in this assay. To determine whether the interaction of 
cryptophycin 1 with tubulin is freely reversible, tubulin was 
incubated with cryptophycin 1 for 15 min and passed through 
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Fig. 1. Structure of cryptophycin 1.
Sephadex G-25 by column centrifugation after which the pro- 
tein was tested for its ability to assemble. It was found that 
tubulin assembly was still inhibited, indicating that the rate of 
dissociation of the tubulin-cryptophycin 1 complex is slow. 
Size exclusion-HPLC was used to determine whether crypto- 
phycin 1 causes aggregation of tubulin. Chromatography of
tubulin in PEM buffer containing cryptophycin 1 leads to the 
formation of a species with a molecular mass greater than that 
of the tubulin dimer (Fig. 3). The elution pattern for tubulin 
showed a major peak for the dimer, with an elution time of 
16 rain, and a smaller aggregate peak eluting at the void volume. 
After incubation with cryptophycin 1 for 20 rain at room tem- 
perature, the profile showed the major peak eluting with the 
void volume, with a small shoulder at the elution time for the 
tubulin dimer. This result is very similar to that observed with 
Vinca alkaloids [9]. 
When Vinca alkaloids are added to microtubules formed 
from microtubule protein (tubulin containing microtubule-as- 
sociated proteins), individual protofilaments splay from the 
ends of the microtubules and form spiral structures [12,13]. A 
similar phenomenon occurs with cryptophycin 1.Cryptophycin 
1 (40 #M) was added to microtubules at steady state and incu- 
bated at 37°C. Electron microscopic examination showed the 
formation of aggregates, ome attached to the ends ofmicrotu- 
bules (Fig. 4A). The aggregates show some indication of a loose 
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Fig. 2. Inhibition of tubulin assembly by cryptophycin 1.The amount 
of tubulin polymerized in 15 min is plotted against cryptophycin 1 
concentration. Details are given in section 2. 
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Fig. 3. Size-exclusion HPLC of the tubulin-cryptophycin 1 complex. 
After incubation of 5 #M tubulin with or without 5 #M cryptophycin 
1 in PEM buffer for 20 min at room temperature, the sample was 
chromatographed on a 600 × 7.8 mm Phenomenex Biospec-sec S-2000 
column using a flow rate of 0.8 ml/min. Molecular weight markers were 
used to calibrate the column; 670 kDa = thyroglobulin, 44 kDa = 
ovalbumin. (A) Tubulin alone. (B) Tubulin plus cryptophycin 1.
helical substructure that resembles the spirals produced by the 
Vinca alkaloids, but appear to be more irregular than the latter 
(Fig. 4B). Further detailed structural analysis is required before 
it is possible to say whether these structures are identical to the 
spiraled protofilaments formed after Vinca drug treatment. 
Fig. 4. Effect ofcryptophycin 1 and VLB on microtubules. Microtubule 
protein (2.5 mg/ml) was polymerized inPEM buffer containing 0.5 mM 
GTP. Cryptophycin 1 (40 #M) or VLB (40 ,uM) were added and incu- 
bation was continued at 37°C for 20 min. Samples were then removed 
for negative staining. (A) Cryptophycin 1.(B) VLB. 
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Fig. 5. Inhibition of VLB binding by cryptophycin 1. [3H]VLB was 
incubated with tubulin in the presence of varying concentrations of 
cryptophycin 1 before centrifugation through a column of Sephadex 
G-25. Details are given in section 2. 
3.2. Effect on VLB and colchicine binding 
VLB binding was measured by separating free and bound 
drug by column centrifugation [9]. Fig. 5 shows the inhibition 
of [3H]VLB binding by cryptophycin 1. Clearly, cryptophycin 
1 is an effective inhibitor of VLB binding, with 6 pM causing 
a 50% reduction in binding at a total VLB concentration of 5 
pM. Whether this inhibition is due to an interaction at the 
Vinca site or is due to the aggregating properties of crypto- 
phycin 1 is not clear at this time. 
Colchicine binding was measured by taking advantage of the 
fluorescence which develops when the drug binds to tubulin. 
Upon incubation of 3 pM tubulin with 6 /zM colchicine a 
time-dependent i crease in relative fluorescence occurred at 
432 nm. The presence of a 5-fold molar excess of cryptophycin 
1 over colchicine had no effect on the development of the 
fluorescence. On the other hand, a 2.5-fold molar excess of 
podophyllotoxin over colchicine completely prevented the in- 
crease in fluorescence. 
4. Conclusions 
Cryptophycin 1, a newly described natural product from the 
cyanobacterium Nostoc, shows properties similar to the Vinca 
alkaloids. It inhibits tubulin polymerization substoichiometri- 
cally, disassembles microtubules containing associated proteins 
to linear structures omewhat similar to the spiraled proto- 
filaments produced by the Vinca drugs, and causes tubulin to 
aggregate. Moreover, it inhibits VLB binding to tubulin but not 
binding of colchicine. Thus, cryptophycin 1 belongs to an ever 
growing list of compounds that apparently interact with the 
Vinca domain in tubulin, a list which includes maytansine, 
dolastatin 10, phomopsin A, halichondrin B (for a review, see 
[14]), and spongistatins [15]. Although cryptophycin 1 does 
appear to bind to the Vinca site, it bears no structural similarity 
to the Vinca alkaloids and it is possible that the cryptophycins 
bind to a site on tubulin which overlaps the Vinca alkaloid site. 
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